drugset / Trial / NCT04642924
SGM-101 in Locally Advanced and Recurrent Rectal Cancer
Phase 2/3
Unknown
203 enrolled
Leiden University Medical Center
Amsterdam UMC, location VUmc · collabCatharina Ziekenhuis Eindhoven · collabCentre for Human Drug Research, Netherlands · collabErasmus Medical Center · collabMedical Center Haaglanden · collabQuest Medical Imaging · collabSurgimab · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Near-infrared fluorescence-guided oncologic surgery (EGOS) with the use of a tumor specific tracer (SGM-101) developed by Surgimab can provide valuable intra-operative information about tumor location and extensiveness, which can be difficult to detect with conventional visual and tactile feedback. Hence, this information could aid in intra-operative decision making and therewith foster complete resection margins and less extensive surgery. Subsequently, this may drastically improve patient care by improving oncologic outcome.
Timeline
- Start
- 2019-10-22
- Primary completion
- 2021-10
- Completion
- 2023-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SGM-101 | Monoclonal antibody | 10 mg | — |